| International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... Blood, The Journal of the American Society of Hematology 126 (3), 291-299, 2015 | 1300 | 2015 |
| Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML AE Perl, G Martinelli, JE Cortes, A Neubauer, E Berman, S Paolini, ... New England Journal of Medicine 381 (18), 1728-1740, 2019 | 1023 | 2019 |
| Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised … RK Hills, S Castaigne, FR Appelbaum, J Delaunay, S Petersdorf, M Othus, ... The lancet oncology 15 (9), 986-996, 2014 | 731 | 2014 |
| Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism T Farge, E Saland, F De Toni, N Aroua, M Hosseini, R Perry, C Bosc, ... Cancer discovery 7 (7), 716-735, 2017 | 708 | 2017 |
| High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis A Jaccard, P Moreau, V Leblond, X Leleu, L Benboubker, O Hermine, ... New England Journal of Medicine 357 (11), 1083-1093, 2007 | 585 | 2007 |
| Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure T Prébet, SD Gore, B Esterni, C Gardin, R Itzykson, S Thepot, F Dreyfus, ... Journal of Clinical Oncology 29 (24), 3322, 2011 | 519 | 2011 |
| Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support E Azoulay, C Alberti, C Bornstain, G Leleu, D Moreau, C Recher, ... Critical care medicine 29 (3), 519-525, 2001 | 472 | 2001 |
| Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice JE Sarry, K Murphy, R Perry, PV Sanchez, A Secreto, C Keefer, ... The Journal of clinical investigation 121 (1), 384-395, 2011 | 461 | 2011 |
| Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine R Itzykson, S Thépot, B Quesnel, F Dreyfus, O Beyne-Rauzy, P Turlure, ... Blood, The Journal of the American Society of Hematology 117 (2), 403-411, 2011 | 456 | 2011 |
| Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised … C Récher, B Coiffier, C Haioun, TJ Molina, C Fermé, O Casasnovas, ... The Lancet 378 (9806), 1858-1867, 2011 | 439 | 2011 |
| Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study C Berthon, E Raffoux, X Thomas, N Vey, C Gomez-Roca, K Yee, ... The Lancet Haematology 3 (4), e186-e195, 2016 | 435 | 2016 |
| Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy R Moschoi, V Imbert, M Nebout, J Chiche, D Mary, T Prebet, E Saland, ... Blood, The Journal of the American Society of Hematology 128 (2), 253-264, 2016 | 404 | 2016 |
| Antileukemic activity of rapamycin in acute myeloid leukemia C Récher, O Beyne-Rauzy, C Demur, G Chicanne, C Dos Santos, ... Blood 105 (6), 2527-2534, 2005 | 397 | 2005 |
| Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia E Jourdan, N Boissel, S Chevret, E Delabesse, A Renneville, P Cornillet, ... Blood, The Journal of the American Society of Hematology 121 (12), 2213-2223, 2013 | 393 | 2013 |
| Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition N Jacque, AM Ronchetti, C Larrue, G Meunier, R Birsen, L Willems, ... Blood, The Journal of the American Society of Hematology 126 (11), 1346-1356, 2015 | 372 | 2015 |
| Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience L Ades, A Guerci, E Raffoux, M Sanz, P Chevallier, S Lapusan, C Recher, ... Blood, The Journal of the American Society of Hematology 115 (9), 1690-1696, 2010 | 347 | 2010 |
| Expression and prognostic significance of survivin in de novo acute myeloid leukaemia C Adida, C Recher, E Raffoux, MT Daniel, AL Taksin, P Rousselot, ... British journal of haematology 111 (1), 196-203, 2000 | 299 | 2000 |
| Incidence and risk factors for central nervous system occurrencein elderly patients with diffuse large-B-cell lymphoma: influenceof rituximab P Feugier, JM Virion, H Tilly, C Haioun, G Marit, M Macro, D Bordessoule, ... Annals of Oncology 15 (1), 129-133, 2004 | 295 | 2004 |
| MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study C Copie-Bergman, P Cuillière-Dartigues, M Baia, J Briere, R Delarue, ... Blood, The Journal of the American Society of Hematology 126 (22), 2466-2474, 2015 | 276 | 2015 |
| Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia P Montesinos, C Recher, S Vives, E Zarzycka, J Wang, G Bertani, ... New England Journal of Medicine 386 (16), 1519-1531, 2022 | 246 | 2022 |
